Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transarterial PD-1 Antibody with TACE and HAIC for Unresectable HCC
NCT04814030Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 12 months. Status: unknown.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04814030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814030.